Overview on therapeutic applications of microparticulate drug delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 33, Issue 4, 2016, Pages 309-361

  Bale, Swarna ^a   Khurana, Amit ^a   Reddy, A Shiva Shankar ^a   Singh, Mandip ^b   Godugu, Chandraiah ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Drug delivery; Microparticles; Sustained release; Therapeutic benefits

Indexed keywords

ALPHA CRYSTALLIN; AMYLOID BETA PROTEIN; ARGININE; CAPTOPRIL; CARVEDILOL; CHOLERA TOXIN; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; DOXORUBICIN; EXENDIN 4; GALACTOSYLCERAMIDE; GEMCITABINE; GLIBENCLAMIDE; GLIPIZIDE; HOLMIUM; IMIQUIMOD; INSULIN; METFORMIN; NATEGLINIDE; OVALBUMIN; PACLITAXEL; POLYMER; PROTAMINE; REPAGLINIDE; ROSIGLITAZONE; ROTIGOTINE; TACRINE; THYMOSIN BETA4; TUMOR VACCINE; UNINDEXED DRUG; DELAYED RELEASE FORMULATION; DRUG; DRUG CARRIER; MICROCAPSULE; MICROSPHERE; VACCINE;

ARTICLE; BIOCOMPATIBILITY; BRAIN TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CARDIOVASCULAR DISEASE; CROSS LINKING; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SPECIFICITY; DRUG STABILITY; EMULSION; EVAPORATION; GELATION; GLIOMA; KIDNEY CANCER; LUNG CANCER; MICROENCAPSULATION; MICROPARTICULATE DRUG DELIVERY SYSTEM; NEUROLOGIC DISEASE; PARTICULATE MATTER; POLYMERIZATION; PROSTATE CANCER; VACCINE IMMUNOGENICITY; ADMINISTRATION AND DOSAGE; CARDIOVASCULAR DISEASES; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG FORMULATION; GENE TRANSFER; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; MICROCAPSULE; NEOPLASMS; NERVOUS SYSTEM DISEASES; PARTICLE SIZE; POROSITY; PROCEDURES; THERAPEUTIC USE; TRENDS;

ADMINISTRATION, OPHTHALMIC; CAPSULES; CARDIOVASCULAR DISEASES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; GENE TRANSFER TECHNIQUES; HUMANS; MICROSPHERES; NEOPLASMS; NERVOUS SYSTEM DISEASES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POLYMERS; POROSITY; VACCINES;

EID: 85013223257     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2016015798     Document Type: Article

References (202)

1. Jyothi NVN, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan G. Microencapsulation techniques, factors influencing encapsulation efficiency. J Microencapsul. 2010;27(3):187–97.
2. Yoon YM, Lewis JS, Carstens MR, Campbell-Thompson M, Wasserfall CH, Atkinson MA, Keselowsky BG. A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Sci Rep. 2015;5.
3. Ballesteros NA, Alonso M, Saint-Jean SR, Perez-Prieto SI. An oral DNA vaccine against infectious haematopoietic necrosis virus (IHNV) encapsulated in alginate microspheres induces dose-dependent immune responses and significant protection in rainbow trout (Oncorrhynchus mykiss). Fish Shellfish Immunol. 2015;45(2):877–88.
4. Hasan AS, Sapin A, Damgé C, Leroy P, Socha M, Maincent P. Reduction of the in vivo burst release of insulin-loaded microparticles. J Drug Deliv Sci Technol. 2015;30:486–93.
5. Ozeki T, Kano Y, Takahashi N, Tagami T, Okada H. Improved bioavailability of a water-insoluble drug by inhalation of drug-containing maltosyl-β-cyclodextrin microspheres using a four-fluid nozzle spray drier. AAPS PharmSciTech. 2012;13(4):1130–7.
6. Li SP, Kowarski CR, Feld KM, Grim WM. Recent advances in microencapsulation technology and equipment. Drug Dev Ind Pharm. 1988;14(2–3):353–76.
7. Aggarwal A, Chhajer P, Maheshwari S. Magnetic drug delivery in therapeutics. Int J Pharm Sci Res. 2012;3(12):4670.
8. Naveena H, Nesalin JAJ, Mani TT. Preparation and characterization of microspheres encapsulating ritonavir by solvent evaporation technique. Imperial Journal of Interdisciplinary Research. 2016;2(2):64–72.
9. Beck-Broichsitter M, Stoisiek K, Bohr A, Aragão-Santiago L, Gessler T, Seeger W, Kissel T. Potential of the isolated lung technique for the examination of sildenafil absorption from lung-delivered poly (lactide-co-glycolide) microparticles. J Control Release. 2016;226:15–20.
10. Al-Nimry SS, Khanfar MS. Preparation and characterization of lovastatin polymeric microparticles by coacervation-phase separation method for dissolution enhancement. J Appl Polym Sci. 2016;133(14):43277–86.
11. Jain N. Targeted and controlled drug delivery. New Delhi: CBS Publishers and Distributors; 2002.
12. Liu H, Gong J, Chabot D, Miller SS, Cui SW, Ma J, Zhong F, Wang Q. Incorporation of polysaccharides into sodium caseinate-low melting point fat microparticles improves probiotic bacterial survival during simulated gastrointestinal digestion and storage. Food Hydrocolloids. 2016;54:328–37.
13. Kumar A, Lahiri SS, Punyani S, Singh H. Synthesis and characterization of pH sensitive poly (PEGDMA-MAA) copolymeric microparticles for oral insulin delivery. J Appl Polym Sci. 2008;107(2):863–71.
14. Sajeesh S, Vauthier C, Gueutin C, Ponchel G, Sharma CP. Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomater. 2010;6(8):3072–80.
15. Amancha KP, Balkundi S, Lvov Y, Hussain A. Pulmonary sustained release of insulin from microparticles composed of polyelectrolyte layer-by-layer assembly. Int J Pharm. 2014;466(1):96–108.
16. D’Souza B, Bhowmik T, Uddin MN, Oettinger C, D’Souza M. Development of β-cyclodextrin-based sustained release microparticles for oral insulin delivery. Drug Dev Ind Pharm. 2015;41(8):1288–93.
17. Yu F, Li Y, Liu CS, Chen Q, Wang GH, Guo W, Wu XE, Li DH, Wu WD, Chen XD. Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin. Int J Pharm. 2015;484(1):181–91.
18. Shrestha N, Shahbazi MA, Araújo F, Zhang H, Mäkilä EM, Kauppila J, Sarmento B, Salonen JJ, Hirvonen JT, Santos HA. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials. 2014;35(25):7172–9.
19. Sonia T, Rekha M, Sharma CP. Bioadhesive hydrophobic chitosan microparticles for oral delivery of insulin: in vitro characterization and in vivo uptake studies. J Appl Polym Sci. 2011;119(5):2902–10.
20. Rekha M, Sharma CP. Glutamine-chitosan microparticles as oral insulin delivery matrix: in vitro characterization. J Appl Polym Sci. 2011;122(4):2374–82.
21. Leong KH, Chung LY, Noordin MI, Onuki Y, Morishita M, Takayama K. Lectin-functionalized carboxymethylated kappa-carrageenan microparticles for oral insulin delivery. Carbohydr Polym. 2011;86(2):555–65.
22. Kim H, Lee J, Kim TH, Lee ES, Oh KT, Lee DH, Park ES, Bae YH, Lee KC, Youn YS. Albumin-coated porous hollow poly (lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res. 2011;28(8):2008–19.
23. Lim SM, Eom HN, Jiang HH, Sohn M, Lee KC. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy. J Pharm Sci. 2015;104(1):72–80.
24. Liu B, Dong Q, Wang M, Shi L, Wu Y, Yu X, Shi Y, Shan Y, Jiang C, Zhang X, Gu T, Chen Y, Kong W. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly (DL-lactic-co-glycolic acid) microspheres. Chem Pharm Bull (Tokyo). 2010;58(11):1474–9.
25. Zhu C, Huang Y, Zhang X, Mei L, Pan X, Li G, Wu C. Comparative studies on exenatide-loaded poly (d, l-lactic-co-glycolic acid) microparticles prepared by a novel ultra-fine particle processing system and spray drying. Colloids Surf B Biointerfaces. 2015;132:103–10.
26. Soudry-Kochavi L, Naraykin N, Nassar T, Benita S. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. J Control Release. 2015;217:202–10.
27. Millotti G, Vetter A, Leithner K, Sarti F, Shahnaz Bano G, Augustijns P, Bernkop-Schnürch A. Development of thiolated poly (acrylic acid) microparticles for the nasal administration of exenatide. Drug Dev Ind Pharm. 2014;40(12):1677–82.
28. Choudhury PK, Kar M. Controlled release metformin hydrochloride microspheres of ethyl cellulose prepared by different methods and study on the polymer affected parameters. J Microencapsul. 2009;26(1):46–53.
29. Maji R, Ray S, Das B, Nayak AK. Ethyl cellulose microparticles containing metformin HCl by emulsification-solvent evaporation technique: effect of formulation variables. ISRN Polym Sci. 2012;2012:801827.
30. Deb J. Formulation and evaluation of carbopol microspheres of metformin HCl. Asian J Biomed Pharm Sci. 2011;1(2):11–9.
31. Banerjee P, Deb J, Roy A, Ghosh A, Chakraborty P. Fabrication and development of pectin microsphere of metformin hydrochloride. ISRN Pharm. 2012;2012:230621.
32. Cetin M, Sahin S. Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride. Drug Deliv. 2015:1–10.
33. Rathnam G, Balasubramani P, Saravanakumar A. Nasal drug delivery of anti-diabetic drug repaglinide using degradable starch microspheres. Int J Pharm Sci Res. 2011;2(4):940.
34. Jain SK, Sahoo AK, Gupta M, Pandey AN, Kumar A, Jain AK. Delivery of repaglinide–cholestyramine complex loaded ethylcellulose microspheres to gastric mucosa for effective management of type-2 diabetes mellitus. Curr Sci. 2014;106(11):1518.
35. Gaba P, Singh S, Gaba M, Gupta G. Galactomannan gum coated mucoadhesive microspheres of glipizide for treatment of type 2 diabetes mellitus: in vitro and in vivo evaluation. Saudi Pharmaceutical Journal. 2011;19(3):143–52.
36. Senthil A, Sivakumar T, Narayanaswamy V. Mucoadhesive microspheres of oral anti diabetic drug-glipizide using different polymers. Der Pharmacia Lettre. 2011;201(3):496–506.
37. Sharma VK, Mazumder B. Gastrointestinal transition and anti-diabetic effect of Isabgol husk microparticles containing gliclazide. Int J Biol Macromol. 2014;66:15–25.
38. Devarajan PV, Sonavane GS. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm. 2007;33(2):101–11.
39. Pal D, Nayak AK. Novel tamarind seed polysaccharide-alginate mucoadhesive microspheres for oral gliclazide delivery: in vitro–in vivo evaluation. Drug Deliv. 2012;19(3):123–31.
40. Mathavan S, Chen-Tan N, Arfuso F, Al-Salami H. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. Drug Deliv. 2015:1–12.
41. Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, Fakhoury M, Arfuso F, Al-Salami H. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151–6.
42. Kumar BP, Chandiran IS, Jayaveera KN. Formulation development and evaluation of glibenclamide loaded Eudragit RLPO microparticles. International Current Pharmaceutical Journal. 2013;2(12): 196–201.
43. Rao BP, Baby B, Mathews R, Rajarajan S, Haritha P, Ramesh K, Gupta NV. Design, statistical optimisation, characterisation and pharmacodynamic studies on pioglitazone hydrochloride floating microparticles. J Microencapsul. 2014;31(4):406–14.
44. Lewis JS, Dolgova NV, Zhang Y, Xia CQ, Wasserfall CH, Atkinson MA, Clare-Salzler MJ, Keselowsky BG. A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice. Clin Immunol. 2015;160(1):90–102.
45. Wang X, Sng MK, Foo S, Chong HC, Lee WL, Tang MB, Ng KW, Luo B, Choong C, Wong MT, Tong BM, Chiba S, Loo SC, Zhu P, Tan NS. Early controlled release of peroxisome proliferator-activated receptor β/δ agonist GW501516 improves diabetic wound healing through redox modulation of wound microenvironment. J Control Release. 2015;197:138–47.
46. Links MR, Taylor J, Kruger MC, Naidoo V, Taylor JR. Kafirin microparticle encapsulated sorghum condensed tannins exhibit potential as an anti-hyperglycaemic agent in a small animal model. Journal of Functional Foods. 2016;20:394–9.
47. Poole KM, Nelson CE, Joshi RV, Martin JR, Gupta MK, Haws SC, Kavanaugh TE, Skala MC, Duvall CL. ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease. Biomaterials. 2015;41:166–75.
48. Chime SA, Onyishi IV, Ugwoke PU, Attama AA. Evaluation of the properties of Gongronema latifolium in phospholipon 90H based solid lipid microparticles (SLMs): an antidiabetic study. J Diet Suppl. 2014;11(1):7–18.
49. Bosio VE, Cacicedo ML, Calvignac B, León I, Beuvier T, Boury F, Castro GR. Synthesis and characterization of CaCO 3–biopolymer hybrid nanoporous microparticles for controlled release of doxorubicin. Colloids Surf B Biointerfaces. 2014;123:158–69.
50. Sajeesh S, Vauthier C, Gueutin C, Ponchel G, Sharma CP. Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomater. 2010;6(8):3072–80.
51. Garud A, Garud N. Formulation of mucoadhesive microspheres of rosiglitazone maleate and its in vitro evaluation using ionotropic gelation technique. Ars Pharm. 2015;56(2):101–7.
52. Attama A, Nwabunze O. Mucuna gum microspheres for oral delivery of glibenclamide: in vitro evaluation. Acta Pharm. 2007;57(2):161–71.
53. Kajjari PB, Manjeshwar LS, Aminabhavi TM. Novel blend microspheres of cellulose triacetate and bee wax for the controlled release of nateglinide. Journal of Industrial and Engineering Chemistry. 2014;20(2):397–404.
54. Pandya N, Pandya M, Bhaskar V. Preparation and in vitro characterization of porous carrier-based glipizide floating microspheres for gastric delivery. Journal of Young Pharmacists. 2011;3(2):97–104.
55. Cruz LJ, Tacken PJ, Rueda F, Carles Domingo J, Albericio F, Figdor CG. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol. 2012;509:143.
56. T O’Hagan D, Singh M, Gupta RK. Poly (lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev. 1998;32(3):225–46.
57. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57(3):391–410.
58. Mathew S, Lendlein A, Wischke C. Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery. Eur J Pharm Biopharm. 2014;87(2):403–7.
59. Makkouk A, Joshi VB, Lemke CD, Wongrakpanich A, Olivier AK, Blackwell SE, Salem AK, Weiner GJ. Three steps to breaking immunotolerance to lymphoma: a microparticle approach. Cancer Immunol Res. 2015;3:389–98.
60. Wang Q, Tan MT, Keegan BP, Barry MA, Heffernan MJ. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. Biomaterials. 2014;35(29): 8385–93.
61. Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, O’Hagan DT, Donnelly JJ 3rd, Ott G, McDonald DM. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol. 2003;225(1):12-20.
62. Little SR, Lynn DM, Ge Q, Anderson DG, Puram SV, Chen J, Eisen HN, Langer R. Poly-β amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci USA. 2004;101(26):9534–9.
63. Zhou X, Liu B, Yu X, Zha X, Zhang X, Wang X, Jin Y, Wu Y, Chen Y, Shan Y, Chen Y, Liu J, Kong W, Shen J. Controlled release of PEI/DNA complexes from PLGA microspheres as a potent delivery system to enhance immune response to HIV vaccine DNA prime/MVA boost regime. Eur J Pharm Biopharm. 2008;68(3):589–95.
64. Martínez Gómez JM, Csaba N, Fischer S, Sichelstiel A, Kündig TM, Gander B, Johansen P. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J Control Release. 2008;130(2):161–7.
65. Krishnamachari Y. PLGA microparticle based vaccine carriers for an improved and efficacious tumor therapy [dissertation]. Iowa City, IA: University of Iowa; 2011.
66. Rajkannan R, Arul V, Malar E, Jayakumar R. Preparation, physiochemical characterization, and oral immunogenicity of Aβ (1–12), Aβ (29–40), and Aβ (1–42) loaded PLG microparticles formulations. J Pharm Sci. 2009;98(6):2027–39.
67. Beaudette TT, Bachelder EM, Cohen JA, Obermeyer AC, Broaders KE, Fréchet JM, Kang ES, Mende I, Tseng WW, Davidson MG, Engleman EG. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm. 2009;6(4):1160–9.
68. Bachelder EM, Beaudette TT, Broaders KE, Fréchet JM, Albrecht MT, Mateczun AJ, Ainslie KM, Pesce JT, Keane-Myers AM. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm. 2010;7(3):826–35.
69. Zhang W, Wang L, Yang T, Liu Y, Chen X, Liu Q, Jia J, Ma G. Immunopotentiator-loaded polymeric microparticles as robust adjuvant to improve vaccine efficacy. Pharm Res. 2015;32(9):2837–50.
70. Anugraha G, Madhumathi J, Prita PJJ, Kaliraj P. Biodegradable poly-l-lactide based microparticles as controlled release delivery system for filarial vaccine candidate antigens. Eur J Pharmacol. 2015;747:174–80.
71. Zhang W, Wang L, Liu Y, Chen X, Li J, Yang T, An W, Ma X, Pan R, Ma G. Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis. Pharm Res. 2014;31(4):1015–31.
72. Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol Pharm. 2011;9(1):81–90.
73. Nimtrakul P, Atthi R, Limpeanchob N, Tiyaboonchai W. Development of Pasteurella multocida-loaded microparticles for hemorrhagic septicemia vaccine. Drug Dev Ind Pharm. 2015;41(3):423–9.
74. Pastor M, Esquisabel A, Marquínez I, Talavera A, Pedraz JL. Cellulose acetate phthalate microparticles containing Vibrio cholerae: steps toward an oral cholera vaccine. J Drug Target. 2014;22(6): 478–87.
75. Moreno-Mendieta S, Guillen D, Espitia C, Hernandez-Pando R, Sánchez S, Rodríguez-Sanoja R. A novel antigen-carrier system: the Mycobacterium tuberculosis Acr protein carried by raw starch microparticles. Int J Pharm. 2014;474(1):241–8.
76. Shastri PN, Kim MC, Quan FS, D’Souza MJ, Kang SM. Immunogenicity and protection of oral influenza vaccines formulated into microparticles. J Pharm Sci. 2012;101(10):3623–35.
77. Chablani L, Tawde SA, D’souza MJ. Spray-dried microparticles: a potential vehicle for oral delivery of vaccines. J Microencapsul. 2012;29(4):388–97.
78. Sitta DL, Guilherme MR, Garcia FP, Cellet TS, Nakamura CV, Muniz EC, Rubira AF. Covalent albumin microparticles as an adjuvant for production of mucosal vaccines against hepatitis B. Biomacromolecules. 2013;14(9):3231–7.
79. DeLyria ES, Zhou D, Lee JS, Singh S, Song W, Li F, Sun Q, Lu H, Wu J, Qiao Q, Hu Y, Zhang G, Li C, Sastry KJ, Shen H. Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity. Carbohydr Res. 2015;405:87–92.
80. Joshi VB, Geary SM, Gross BP, Wongrakpanich A, Norian LA, Salem AK. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Exp Rev Vaccines. 2014;13(1):9–15.
81. Jiang T, Singh B, Li HS, Kim YK, Kang SK, Nah JW, Choi YJ, Cho CS. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials. 2014;35(7):2365–73.
82. Gross BP, Wongrakpanich A, Francis MB, Salem AK, Norian LA. A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. AAPS J. 2014;16(6):1194–203.
83. Dierendonck M, Fierens K, De Rycke R, Lybaert L, Maji S, Zhang Z, Zhang Q, Hoogenboom R, Lambrecht BN, Grooten J, Remon JP, De Koker S, De Geest BG. Nanoporous hydrogen bonded polymeric microparticles: facile and economic production of cross presentation promoting vaccine carriers. Advanced Functional Materials. 2014;24(29):4634–44.
84. De Koker S, Fierens K, Dierendonck M, De Rycke R, Lambrecht BN, Grooten J, Remon JP, De Geest BG. Nanoporous polyelectrolyte vaccine microcarriers: a formulation platform for enhancing humoral and cellular immune responses. J Control Release. 2014;195:99–109.
85. Snook JD, Chesson CB, Peniche AG, Dann SM, Paulucci A, Pinchuk IV, Rudra JS. Peptide nanofiber-CaCO 3 composite microparticles as adjuvant-free oral vaccine delivery vehicles. J Mater Chem B. 2016;4:1640–9.
86. De Smet R, Verschuere S, Allais L, Leclercq G, Dierendonck M, De Geest BG, Van Driessche I, Demoor T, Cuvelier CA. Spray-dried polyelectrolyte microparticles in oral antigen delivery: stability, biocompatibility, and cellular uptake. Biomacromolecules. 2014;15(6):2301–9.
87. Deng Y, Mathaes R, Winter G, Engert J. Encapsulation of antigen-loaded silica nanoparticles into microparticles for intradermal powder injection. Eur J Pharm Sci. 2014;63:154–66.
88. Weissmueller NT, Schiffter HA, Carlisle RC, Rollier CS, Pollard AJ. Needle-free dermal delivery of a diphtheria toxin CRM197 mutant on potassium-doped hydroxyapatite microparticles. Clin Vaccine Immunol. 2015;22(5):586–92.
89. Silber JH, Barber G, Paz-Ares L, Dobbs N, Twelves C. doxorubicin-induced cardiotoxicity. N Engl J Med. 1995;333:1359–60.
90. Stewart J, Bolt H. cisplatin-induced nephrotoxicity. Arch Toxicol. 2012;86(8):1155–6.
91. Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988;48(10):2641–58.
92. Rahimian S, Fransen MF, Kleinovink JW, Amidi M, Ossendorp F, Hennink WE. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials. 2015;61:33–40.
93. Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res. 2010;70(11):4443–52.
94. Feng G, Liu J, Geng J, Liu B. Conjugated polymer microparticles for selective cancer cell image-guided photothermal therapy. J Mater Chem B. 2015;3(6):1135–41.
95. Makkouk A, Joshi VB, Wongrakpanich A, Lemke CD, Gross BP, Salem AK, Weiner GJ. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J. 2015;17(1):184–93.
96. Jabr-Milane L, van Vlerken L, Devalapally H, Shenoy D, Komareddy S, Bhavsar M, Amiji M. Multifunctional nanocarriers for targeted delivery of drugs and genes. J Control Release. 2008;130(2):121–8.
97. Prabhakar M, Song JI, Chowdoji Rao K. Collagen-coated lapatinib-loaded poly (lactic acid) microspheres for breast cancer in biomedical applications. Advances in Polymer Technology. 2015;34(4):1098–2329.
98. Almond BA, Hadba AR, Freeman ST, Cuevas BJ, York AM, Detrisac CJ, Goldberg EP. Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer. J Control Release. 2003;91(1):147–55.
99. Mladenovska K, Janevik EI, Glavas MD, Kumbaradzi EF, Goracinova K. Biodistribution of 131I-BSA loaded gelatin microspheres after peroral application to BALB/c mice--particle size study. Acta Pharm. 2003;53(3):187–97.
100. Cheng J, Liu Q, Shuhendler AJ, Rauth AM, Wu XY. Optimizing the design and in vitro evaluation of bioreactive glucose oxidase-microspheres for enhanced cytotoxicity against multidrug resistant breast cancer cells. Colloids Surf B Biointerfaces. 2015;130:164–72.
101. Upadhyay UM, Tyler B, Patta Y, Wicks R, Spencer K, Scott A, Masi B, Hwang L, Grossman R, Cima M, Brem H, Langer R. Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. Proc Natl Acad Sci USA. 2014;111(45):16071–6.
102. Jagadeesh H, Devi V. tamoxifen loaded poly (ε-caprolactone) based injectable microspheres for breast cancer. Int J Pharm Pharmaceut Sci. 2010;2(4):189–95.
103. Sabel MS, Skitzki J, Stoolman L, Egilmez NK, Mathiowitz E, Bailey N, Chang WJ, Chang AE. Intratumoral IL-12 and TNF-α–loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol. 2004;11(2):147–56.
104. Pentyala SN, Lee J, Hsieh K, Waltzer WC, Trocchia A, Musacchia L, Rebecchi MJ, Khan SA. Prostate cancer: a comprehensive review. Med Oncol. 2000;17(2):85-105.
105. Fitzpatrick JM. New developments in the pharmacological management of prostate cancer. BJU Int. 2000;85(s2):31–7.
106. Moul JW. Contemporary hormonal management of advanced prostate cancer. Oncology (Williston Park). 1998;12(4):499–505.
107. Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the dunning R-3327H rat prostate cancer model. Prostate. 1992;20(4):297–310.
108. Rao W, Zhao S, Yu J, Lu X, Zynger DL, He X. Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials. 2014;35(27):7762–73.
109. Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther. 2008;7(7):1864–70.
110. Becker AL, Orlotti NI, Folini M, Cavalieri F, Zelikin AN, Johnston AP, Zaffaroni N, Caruso F. Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano. 2011;5(2):1335–44.
111. Xie J, Marijnissen JCM, Wang CH. Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro. Biomaterials. 2006;27(17): 3321–32.
112. Xie J, Tan RS, Wang CH. Biodegradable microparticles and fiber fabrics for sustained delivery of cisplatin to treat C6 glioma in vitro. J Biomed Mater Res A. 2008;85(4):897–908.
113. Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Stein-bacher JL, Butnor KJ, Ramos-Niño ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman BT. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer. 2011;129(1):233–44.
114. Lin R, Ng LS, Wang CH. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials. 2005;26(21):4476–85.
115. Nanthakumaran S, Brown I, Heys SD, Schofield AC. Inhibition of gastric cancer cell growth by arginine: molecular mechanisms of action. Clin Nutr. 2009;28(1):65–70.
116. Wolf C, Bruess M, Haenisch B, Goethert M, von Kuegelgen I, Molderings GJ. Molecular basis for the antiproliferative effect of agmatine in tumor cells of colonic, hepatic, and neuronal origin. Mol Pharmacol. 2007;71(1):276–83.
117. Lee H-Y, Mohammed KA, Goldberg EP, Nasreen N. Arginine-conjugated albumin microspheres inhibits proliferation and migration in lung cancer cells. Am J Cancer Res. 2013;3(3):266–77.
118. Grinberg O, Gedanken A, Patra CR, Patra S, Mukherjee P, Mukhopadhyay D. Sonochemically prepared BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics. Acta Biomater. 2009;5(8):3031–7.
119. Bult W, Kroeze SG, Elschot M, Seevinck PR, Beekman FJ, de Jong HW, Uges DR, Kosterink JG, Luijten PR, Hennink WE, van het Schip AD, Bosch JL, Nijsen JF, Jans JJ. Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One. 2013;8(1):e52178.
120. Elkharraz K, Faisant N, Guse C, Siepmann F, Arica-Yegin B, Oger JM, Gust R, Goepferich A, Benoit JP, Siepmann J. paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharm. 2006;314(2):127–36.
121. Xie J, Marijnissen JC, Wang CH. Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro. Biomaterials. 2006;27(17): 3321–32.
122. Zhang H, Gao S. temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm. 2007;329(1):122–8.
123. Kim I, Byeon HJ, Kim TH, Lee ES, Oh KT, Shin BS, Lee KC, Youn YS. doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials. 2012;33(22):5574–83.
124. Lee HY, Mohammed KA, Peruvemba S, Goldberg EP, Nasreen N. Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres. J Pharm Pharmacol. 2011;63(11):1401–10.
125. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res. 1964;4(3):139–42.
126. Benoit J-P, Faisant N, Venier-Julienne M-C, Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J Control Release. 2000;65(1):285–96.
127. Yu X, Yao JY, He J, Tian JW. Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres. Life Sci. 2015;124:136–43.
128. Dalpiaz A, Cacciari B, Mezzena M, Strada M, Scalia S. Solid lipid microparticles for the stability enhancement of a dopamine prodrug. J Pharm Sci. 2010;99(11):4730–7.
129. Daviaud N, Garbayo E, Sindji L, Martínez-Serrano A, Schiller PC, Montero-Menei CN. Survival, differentiation, and neuroprotective mechanisms of human stem cells complexed with neurotrophin-3-releasing pharmacologically active microcarriers in an ex vivo model of Parkinson’s disease. Stem Cells Transl Med. 2015;4:670–84.
130. Agbay A, Mohtaram NK, Willerth SM. Controlled release of glial cell line-derived neurotrophic factor from poly (ε-caprolactone) microspheres. Drug Deliv Transl Res. 2014;4(2):159–70.
131. Doddayya H, Srishailgouda SP, Reddy BT, Kumar P, Rajagopal HU, Shree MV. Formulation and evaluation of brain-targeted nasal selegiline hydrochloride microspheres. Int J Pharm. 2014;5(3):61–8.
132. Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer’s disease. J Neurosci Methods. 2009;177(2):427-33.
133. Zhang P, Chen L, Gu W, Xu Z, Gao Y, Li Y. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer’s disease. Biomaterials. 2007;28(10):1882–8.
134. Weissmiller AM, Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012;1(1):1.
135. Saffran BN. Should intracerebroventricular nerve growth factor be used to treat Alzheimer’s disease? Perspect Biol Med. 1992;35(4):471–86.
136. Samal J, Hoban DB, Naughton C, Concannon R, Dowd E, Pandit A. Fibrin-based microsphere reservoirs for delivery of neurotrophic factors to the brain. Nanomedicine. 2015;10(5):765–83.
137. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–9.
138. Cook MJ, O’Brien TJ, Berkovic SF, Murphy M, Morokoff A, Fabinyi G, D’Souza W, Yerra R, Archer J, Litewka L, Hosking S, Lightfoot P, Ruedebusch V, Sheffield WD, Snyder D, Leyde K, Himes D. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol. 2013;12(6):563–71.
139. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia. 2000;41(s2):S42–S52.
140. Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Behav. 2004;5:60–5.
141. Bennewitz MF, Saltzman WM. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics. 2009;6(2):323–36.
142. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003;107(10):1359–65.
143. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2 double-blind, randomized, controlled clinical trial. Circulation. 2002;105(7):788–93.
144. Scott RC, Rosano JM, Ivanov Z, Wang B, Chong PL, Issekutz AC, Crabbe DL, Kiani MF. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009;23(10):3361–7.
145. Wu J, Zeng F, Huang XP, Chung JC, Konecny F, Weisel RD, Li RK. Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials. 2011;32(2):579–86.
146. Formiga FR, Pelacho B, Garbayo E, Abizanda G, Gavira JJ, Simon-Yarza T, Mazo M, Tamayo E, Jauquicoa C, Ortiz-de-Solorzano C, Prósper F, Blanco-Prieto MJ. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. J Control Release. 2010;147(1):30–7.
147. Formiga FR, Garbayo E, Díaz-Herráez P, Abizanda G, Simón-Yarza T, Tamayo E, Prósper F, Blanco-Prieto MJ. Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia. Eur J Pharm Biopharm. 2013;85(3):665–72.
148. Sy JC, Davis ME. Delivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers. J Cardiovasc Transl Res. 2010;3(5):461–8.
149. Seshadri G, Sy JC, Brown M, Dikalov S, Yang SC, Murthy N, Davis ME. The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia-reperfusion injury. Biomaterials. 2010;31(6):1372–9.
150. Vamshi Vishnu Y, Chandrasekhar K, Ramesh G, Madhusudan Rao Y. Development of mucoadhesive patches for buccal administration of carvedilol. Current Drug Deliv. 2007;4(1):27–39.
151. Riekes MK, Barboza FM, Dalla Vecchia D, Bohatch M, Farago PV, Fernandes D, Segatto Silva MA, Stulzer HK. Evaluation of oral carvedilol microparticles prepared by simple emulsion technique using poly (3-hydroxybutyrate-co-3-hydroxyvalerate) and polycaprolactone as polymers. Materials Science and Engineering C. 2011;31(5):962–8.
152. El-Kamel AH, Al-Shora DH, El-Sayed YM. Formulation and pharmacodynamic evaluation of captopril sustained release microparticles. J Microencapsul. 2006;23(4):389–404.
153. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–72.
154. Thatcher JE. Development of poly (lactide-co-glycolide) microspheres for controlled release of thymosin beta-4 in the heart [dissertation]. Dallas: The University of Texas Southwestern Medical Center; 2012.
155. Madonna R, Petrov L, Teberino MA, Manzoli L, Karam JP, Renna FV, Ferdinandy P, Montero-Menei CN, Ylä-Herttuala S, De Caterina R. Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. Cardiovasc Res. 2015;108(1):39–49.
156. Thatcher JE, Welch T, Eberhart RC, Schelly ZA, Michael DiMaio J. Thymosin β4 sustained release from poly (lactide-co-glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia. Ann N Y Acad Sci. 2012;1270(1):112–9.
157. Chen AZ, Tang N, Wang SB, Kang YQ, Song HF. Insulin-loaded poly-l-lactide porous microspheres prepared in supercritical CO 2 for pulmonary drug delivery. The Journal of Supercritical Fluids. 2015;101:117–23.
158. Ramazani F, Hiemstra C, Steendam R, Kazazi-Hyseni F, Van Nostrum CF, Storm G, Kiessling F, Lammers T, Hennink WE, Kok RJ. Sunitinib microspheres based on [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers for ocular drug delivery. Eur J Pharm Biopharm. 2015;95:368–77.
159. Andrés-Guerrero V, Zong M, Ramsay E, Rojas B, Sarkhel S, Gallego B, de Hoz R, Ramírez AI, Salazar JJ, Triviño A, Ramírez JM, Del Amo EM, Cameron N, de-Las-Heras B, Urtti A, Mihov G, Dias A, Herrero-Vanrell R. Novel biodegradable polyesteramide microspheres for controlled drug delivery in ophthalmology. J Control Release. 2015;211:105–17.
160. Sayed EG, Hussein AK, Khaled KA, Ahmed OA. Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system. Drug Des Dev Ther. 2015;9:1427–35.
161. Butoescu N, Seemayer CA, Palmer G, Guerne PA, Gabay C, Doelker E, Jordan O. Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice. Arthritis Res Ther. 2009;11(3):R72.
162. Wang Y, Wan C, Szöke G, Ryaby JT, Li G. Local injection of thrombin-related peptide (TP508) in PPF/PLGA microparticles--enhanced bone formation during distraction osteogenesis. J Orthop Res. 2008;26(4):539–46.
163. Horie RT, Sakamoto T, Nakagawa T, Tabata Y, Okamura N, Tomiyama N, Tachibana M, Ito J. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles. Laryngoscope. 2010;120(2):377–83.
164. Badıllı U, Sen T, Tarımcı N. Microparticulate based topical delivery system of clobetasol propionate. AAPS PharmSciTech. 2011;12(3):949–57.
165. Lee M, Li W, Siu RK, Whang J, Zhang X, Soo C, Ting K, Wu BM. Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein carriers. Biomaterials. 2009;30(30):6094–101.
166. Tan ML, Friedhuber AM, Dunstan DE, Choong PF, Dass CR. The performance of doxorubicin encapsulated in chitosan–dextran sulphate microparticles in an osteosarcoma model. Biomaterials. 2010;31(3):541–51.
167. Dalpiaz A, Gavini E, Colombo G, Russo P, Bortolotti F, Ferraro L, Tanganelli S, Scatturin A, Menegatti E, Giunchedi P. Brain uptake of an anti-ischemic agent by nasal administration of microparticles. J Pharm Sci. 2008;97(11):4889–903.
168. Rui J, Dadsetan M, Runge MB, Spinner RJ, Yaszemski MJ, Windebank AJ, Wang H. Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: in vitro characterization and application in polycaprolactone fumarate nerve conduits. Acta Biomater. 2012;8(2):511–8.
169. Fiore VF, Lofton MC, Roser-Page S, Yang SC, Roman J, Murthy N, Barker TH. Polyketal microparticles for therapeutic delivery to the lung. Biomaterials. 2010;31(5):810–7.
170. Tang J, Liu Z, Zhang Y, Wang L, Li D, Ding J, Jiang X. Fluorofenidone-loaded PLGA microspheres for targeted treatment of paraquat-induced acute lung injury in rats. RSC Advances. 2015;5(38):30153–9.
171. Liang Z, Ni R, Zhou J, Mao S. Recent advances in controlled pulmonary drug delivery. Drug Discov Today. 2015;20(3):380–9.
172. Olsson B, Bondesson E, Borgström L, Edsbäcker S, Eirefelt S, Ekelund K, et al.. Pulmonary drug metabolism, clearance, and absorption. In: Smyth, Hugh D.C., Hickey, Anthony J., editors. Controlled pulmonary drug delivery. New York: Springer; 2011. p. 21-50.
173. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1):1–19.
174. Oberdörster G. Lung clearance of inhaled insoluble and soluble particles. Journal of Aerosol Medicine. 1988;1(4):289–330.
175. Stahlhofen W, Koebrich R, Rudolf G, Scheuch G. Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle size. Journal of Aerosol Science. 1990;21:S407–S410.
176. Lingappan K, Jiang W, Wang L, Couroucli XI, Moorthy B. Sex-specific differences in hyperoxic lung injury in mice: Role of cytochrome P450 (CYP) 1A. Toxicology. 2015;331:14–23.
177. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009;30(10):1947–53.
178. Feng TS, Xu CN, Lin L, Lam MH-W, Liang HJ, Chen XS. doxorubicin-loaded PLGA microparticles with internal pores for long-acting release in pulmonary tumor inhalation treatment. Chinese Journal of Polymer Science. 2015;33(7):947–54.
179. Lee J, Oh YJ, Lee SK, Lee KY. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. J Control Release. 2010;146(1):61–7.
180. Garcia Contreras L, Sung J, Ibrahim M, Elbert K, Edwards D, Hickey A. Pharmacokinetics of inhaled rifampicin porous particles for tuberculosis treatment: insight into rifampicin absorption from the lungs of guinea pigs. Mol Pharm. 2015;12(8):2642–50.
181. Bot AI, Tarara TE, Smith DJ, Bot SR, Woods CM, Weers JG. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res. 2000;17(3):275–83.
182. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, Chen H. Enhanced antitumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32(32):8281–90.
183. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release. 2006;116(2):150–8.
184. Zhang Y, Xiao C, Li M, Ding J, Yang C, Zhuang X, Chen X. Co-delivery of doxorubicin and paclitaxel with linear-dendritic block copolymer for enhanced anticancer efficacy. Science China Chemistry. 2014;57(4):624–32.
185. Lv S, Tang Z, Li M, Lin J, Song W, Liu H, Huang Y, Zhang Y, Chen X. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials. 2014;35(23):6118–29.
186. Feng T, Tian H, Xu C, Lin L, Xie Z, Lam MH, Liang H, Chen X. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm. 2014;88(3):1086–93.
187. Hollander PA. Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes. Medscape General Medicine. 2007;9(1):45.
188. Leone-Bay A, Baughman R, Smutney C, Kocinsky J, Street OC. Innovation in drug delivery by inhalation. On Drug Deliv. 2010;4(7):4–8.
189. Schultz I, Vollmers F, Lühmann T, Rybak JC, Wittmann R, Stank K, Steckel H, Kardziev B, Schmidt M, Högger P, Meinel L. Pulmonary insulin-like growth factor I delivery from trehalose and silk-fibroin microparticles. ACS Biomaterials Science & Engineering. 2015;1(2):119–29.
190. Collins Jr JF, Chinnock RB, Melanson J, Howard J. Ophthalmic drug delivery system. Google Patents; 2011.
191. Ahmed I, Patton T. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985;26(4):584–7.
192. Tataru G, Popa M, Costin D, Desbrieres J. Microparticles based on natural and synthetic polymers for ophthalmic applications. J Biomed Mater Res A. 2012;100(5):1209–20.
193. de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2010;62(1):100–17.
194. Qiu K, Netravali AN. Fabrication and characterization of biodegradable composites based on microfibrillated cellulose and polyvinyl alcohol. Composites Science and Technology. 2012;72(13): 1588–94.
195. Cadinoiu AN, Peptu CA, Fache B, Chailan JF, Popa M. Microparticulated systems based on chitosan and poly (vinyl alcohol) with potential ophthalmic applications. J Microencapsul. 2015;32(4):381–9.
196. Addo RT, Yeboah KG, Siwale RC, Siddig A, Jones A, Ubale RV, Akande J, Nettey H, Patel NJ, Addo E, D’Souza MJ. Formulation and characterization of atropine sulfate in albumin–chitosan microparticles for in vivo ocular drug delivery. J Pharm Sci. 2015;104(5):1677–90.
197. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Ranibizumab for neovascular age-related macular degeneration. American Journal of Health System Pharmacy. 2008;65(19):1805–14.
198. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol. 2007;39(7):1349–57.
199. Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Huijbregts JE, van het Schip AD, Elschot M, Bult W, de Jong HW, Meulenhoff PC, Zonnenberg BA. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res. 2010;29(1):1.
200. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–9.
201. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.
202. Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2012;30(35):4337–43.